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Orofacial anomalies make up about a third of the 120,000 birth defects each year in 
the United States. Children born with these abnormalities must undergo immense physical and 
emotional strain in order to correct the defects. In fact, about $697 million is spent every year 
surgically treating children with cleft lip and/or cleft palate (2011). In countries where surgery 
 is not an option, this abnormality causes immense difficulties in eating, hearing, speech, and 
psychosocial development. The causes of cleft lip/palate are extremely complex. Genetics 
play a role in the anomaly; however, 95% of cleft palate cases are non-syndromic and likely 
due to other factors. Vitamin deficiencies, lack of folic acid intake during pregnancy, 
exposure to cigarette smoke, anticonvulsant drugs, alcohol, and inappropriate amounts of 
retinoic acid have all been correlated to incidence of cleft palate and other orofacial defects  
(Weingartner, Lotz et al. 2007). Xenopus laevis, and the closely related Xenopus tropicalis, 
are excellent model systems for orofacial development studies. The ease of embryo collection 
and manipulation, in addition to the conservation of DNA sequence between the two species, 
makes them ideal for studying developmental processes. Further, tissue specific experiments 
are extremely feasible due to the size of Xenopus oocytes (approximately 1000 times larger 
than a human egg!), and their ability to develop outside of the mother (Lindeman, Winata et 
al. 2010; Liu 2011).  
Here, I show that molecules from both the folic acid and retinoic acid pathways are 
highly expressed in the developing face. I have found that inhibition of key enzymes that 
regulate these pathways induces similar orofacial malformations, including median clefts that 
extend into the developing palate.  Further, disruption of these pathways induces severe 
abnormalities in the formation of the cartilages of the jaws and face. Thus, both folic acid and 
retinoic acid are key signaling molecules that regulate proper formation of the orofacial 
region. 
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Introduction 
 
Development of the orofacial region  
The face is derived from the growth and fusion of five prominences that surround the 
embryonic mouth (stomodeum); the frontonasal prominence, and the paired maxillary and 
mandibular prominences that arise from structures known as pharyngeal arches (Jiang, Bush 
et al. 2006). During neuralation in early development, neural crest cells that contribute to 
neural, skeletal, dermal, and mesenchymal structures, delaminate from the epithelium and 
migrate into these prominences (Cordero, Brugmann et al. 2011).  Beginning at around 26 
days of gestation in humans (E9.5 in mice), neural crest cells originating from the border of 
the future diencephalon migrate into the unpaired frontonasal prominence located dorsal to 
the stomodeum (Jugessur, Farlie et al. 2009). This prominence gives rise to the forehead, the 
region between the eyes, and the top of the nose. At the same time, the cells of the embryonic 
mouth undergo apoptosis, invaginate, intercalate, and migrate, creating the fully formed 
primary mouth opening (Dickinson and Sive 2006).  
Then, by the fifth week in human development (E10 in mice), the nasal placodes 
appear on the ventrolateral edge of the frontonasal prominence, and the ectoderm thickens and 
bulges out to form the lateral and medial nasal prominences (Meng, Bian et al. 2009). The 
medial nasal prominence gives rise to the entire primary palate and the upper lip in mammals. 
Lateral to the stomodeum, are the dorsal paired maxillary prominences and ventral paired 
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mandibular prominences, both of which are derived from the first pharyngeal arch and the 
tissue anterior to it (Rose 2009). Around the same time as nasal prominence formation, rapid 
growth occurs in the mesenchyme of the maxillary prominences, allowing them to enlarge 
and migrate medially toward each other and the lateral and medial nasal prominences. The 
medial nasal prominences then fuse with each other, allowing subsequent fusion of the paired 
maxillary prominences. This entire process then establishes the primary palate and upper lip 
(Meng, Bian et al. 2009). The maxillary prominence also gives rise to skeletal components 
that make up the secondary hard palate and support for the teeth in mammals (Papka 1995). In 
amphibians and fish, this prominence develops into the cartilages such as the paired 
suprarostrals and Meckel’s (MC) that support the upper jaw and face (Altig and McDiarmid 
1999). The structures of the lower mandibular prominence, including the paired infrarostrals 
that articulate with Meckel’s cartilage, make up the structures of the lower jaw (Papka 1995; 
Rose 2009).  
In mammals and amphibians, structures of the hyoid, floor plate of the mouth, and the 
upper portion of the larynx arise from the second pharyngeal arch.  This arch also gives rise to 
important jaw structures such as the basihoyal (BH) and cerathoyal (CH) cartilages found on 
the ventral side of the embryonic face. In amphibians and fish, these structures give support to 
the floor of the mouth. Arches three through six are the brachial arches and give rise to four 
pairs of gills. Gill arches form in a symmetrical, paired pattern corresponding to their 
respective branchial arch (Altig and McDiarmid 1999). In mammals, arches 3, 4, and 6 
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develop into the structural cartilages of the throat, larynx, and pharynx; while arch 5 does not 
result in any adult structures (Netter and Cochard 2002).  
Thus, proper formation of early embryonic prominences is crucial for patterning the 
face, and establishing proper formation of the primary palate and upper lip. This process is 
regulated by several developmental signaling pathways, morphogens, and vitamins; as well as 
signals from ectoderm, mesenchyme, and neural crest (Richman and Lee 2003). Disruption of 
any of these pathways can result in a failure of these prominences to fuse, ultimately leading 
to orofacial clefts.  
 
Cell signaling pathways in orofacial development 
While there is immense phenotypic diversity among adult vertebrate faces, early 
events in facial development are regulated by the same developmental signaling pathways 
across species. It is the subtle differences in expression of genes within these pathways that 
account for the variation in facial morphology (Carroll 2005). From the differences in beak 
size of Darwin’s finches, to the correlation of mutant genes and human disease; gene 
expression analyses have demonstrated that it is this differential gene expression that allows 
for phenotypic diversity both between and within species (Abzhanov, Protas et al. 2004) 
(Mina 2001; Brugmann, Goodnough et al. 2007).  
Expression of genes in major developmental signaling pathways such as BMP, SHH, 
and Wnt is crucial for proper formation of early embryonic prominences that pattern the face 
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(Mina 2001; Brugmann, Goodnough et al. 2007). Communication and crosstalk among these 
pathways is important- as it is also the interaction of endoderm, mesoderm, ectoderm, and 
neural crest that regulates gene expression. This is exemplified by avian studies of the growth 
factor, fgf8. Prior to pharyngeal arch formation, fgf8 is abundantly expressed in the head 
ectoderm. It then becomes highly expressed in the ectoderm of the first pharyngeal arch, and 
is thus important for proper patterning of this structure. Removal of the underlying endoderm 
results in a lack of fgf8 expression in arch ectoderm, suggesting an instructive role of this 
germ layer (Haworth, Wilson et al. 2007). The neural crest, often called the “fourth germ 
layer” is an important cell population that is crucial for neural tube closure and correct facial 
development. The highly conserved Wnt signaling pathway is known to regulate proper 
neural crest migration, and has recently been shown to play a role in regional specification of 
the vertebrate face (Brugmann, Goodnough et al. 2007).  
Another gene family important in early development is the homeobox (hox) gene 
family- famous for their importance in patterning the embryonic body plan (Mallo, Wellik et 
al. 2010). Since their discovery in Drosophila, the timing and location of these transcriptional 
regulators, have proven to be critical not only in establishing the anterior-posterior axis, but 
also in determining cell- type specifications (Inoue, Kawakami et al. 2006). The 
homeodomain containing genes, lhx8 and msx2 have both been shown to be crucial in 
patterning the first pharyngeal arch that gives rise to the palate and upper jaw structures. In 
mouse, lhx8 expression is abundant in the oral mesenchyme throughout palatal growth, 
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elevation, and fusion (Zhang, Mori et al. 2002), and is also expressed in the mesenchyme of 
chick maxillary prominences (Inoue, Kawakami et al. 2006). Further, homozygous lhx8 
knockout mice exhibited complete clefting of the secondary palate, with no other craniofacial 
defects, clearly demonstrating the importance of this gene in palate development (Zhao, Guo 
et al. 1999). The transcriptional repressor, msx2, is also abundantly expressed in the facial 
primordia where epithelial-mesenchymal interactions occur (Alappat, Zhang et al. 2003). 
Indeed, mice with a mutant form of msx2 exhibit a variety of facial deformities, including 
cleft lip and/or cleft palate (Winograd, Reilly et al. 1997).  
Our lab has shown that both MSX2 and LHX8 are regulated by the vitamin A 
derivative, retinoic acid, during orofacial development (Kennedy and Dickinson 2012). 
Inhibition of retinoic acid signaling decreases the expression of both genes, suggesting a 
direct regulation of Msx2 and Lhx8 by retinoic acid (Kennedy and Dickinson 2012). Further, 
retinoic acid has been shown by others to regulate the expression of several other transcription 
factors in the developing facial prominences, such as transforming growth factor beta (TGFβ), 
fibroblast growth factor (FGF), bone morphogenic protein (BMP), endothelian (EDN), and 
sonic hedgehog (SHH) (reviewed in (Richman and Lee 2003)). Thus, proper formation of the 
orofacial region partially relies on proper retinoic acid signaling.  
Like retinoic acid, folic acid is another vitamin derivative important in the developing 
embryo. Folic acid, along with other B vitamins, is a major regulator of DNA synthesis and 
repair (Bohnsack and Hirschi 2004; Friso and Choi 2005) and also generates the methyl 
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donors for histone and DNA methyltransferases to mediate gene and microRNA expression 
(Choi, Friso et al. 2005; Ichi, Costa et al. 2010; Shookhoff and Gallicano 2010). 
Supplementation of folic acid during pregnancy helps prevent orofacial and neural tube 
defects (Finnell, Greer et al. 1998). Indeed folate deficiency has been correlated with facial 
clefting in humans and mice (Hernandez-Diaz, Werler et al. 2000; Vieira, Cooper et al. 2008). 
Clearly, orofacial development is characterized by complex interactions of germ 
layers, neural crest, and transcription factors. Further contributing to this process are extrinsic 
and environmental cues. Retinoic acid and folic acid are important signaling pathways in 
development, and their functional levels are influenced by both environment and maternal 
nutrition. Here I examine the endogenous roles of retinoic and folic acid in face development 
to better understand how changes in maternal nutrition or environmental perturbation may 
cause orofacial defects such as clefts.   
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Chapter 1: The role of retinoic acid in orofacial development 
 
Vitamin A is converted to the signaling molecule, retinoic acid (RA) via a series of 
oxidation reactions. Raldh2 is a key enzyme in this process, and converts the aldehyde form 
of vitamin A into RA. RA can then enter the nucleus and begin signaling through retinoic acid 
receptors (RAR’s) and retinoid X receptors (RXR’s). These elements form heterodimers that 
bind to retinoic acid response elements (RARE’s) in the promoter regions of target genes and 
initiate transcription  (Duester 2008). Due to the importance of retinoic acid in correct 
anterior- posterior patterning of the developing embryo during gastrulation, embryos lacking a 
sufficient amount of retinoic acid often do not make it to term (Durston, Timmermans et al. 
1989). In addition, it is required for proper formation of several organs including, hindbrain, 
spinal cord, heart, eye, lung, pancreas, forelimbs and the craniofacial region (Yasuda, 
Okamoto et al. 1986). For example, Raldh2/Raldh3 double knockout mice exhibit severe 
orofacial defects, including cleft lip (Halilagic, Ribes et al. 2007).Compound knockout of 
murine RARα /RARγ also induces median facial clefts, indicating a role of these receptors in 
facial development (Dupe and Pellerin 2009). An excess of retinoic acid, such as exposure of 
the mother to Accutane during pregnancy, results in the developing embryo surviving past 
birth with craniofacial defects (Malvasi, Tinelli et al. 2009). Interestingly, these defects are 
strikingly similar to the phenotypes seen in retinoic acid deficient mice models (Halilagic, 
Ribes et al. 2007).  Over-expression studies have demonstrated the teratogenic nature of 
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retinoic acid; however, high levels of RA may alter genes not normally controlled by 
endogenous RA. Therefore, loss-of-function experiments are necessary to establish the 
normal function of retinoic acid during development and to determine downstream targets of 
RA signaling (Duester 2008).   
Retinoic acid has been shown to regulate various other signaling molecules and 
transcription factors during orofacial development(Ackermans, Zhou et al. 2011). For 
example, RA regulates expression of the transforming growth factor beta (TGFβ) and 
fibroblast growth factor (FGF) signaling superfamilies in the epithelium of developing facial 
prominences (reviewed in (Richman and Lee 2003)). Further, mis-regulation of these 
signaling molecules results in cleft lip (Barlow and Francis-West 1997; Ashique, Fu et al. 
2002). Retinoic acid is also repeatedly found to regulate bone morphogenic protein (BMP), 
endothelian (EDN), and sonic hedgehog (SHH) pathways; all of which control different 
aspects of the development of the facial prominences (reviewed in(Richman and Lee 2003)). 
Several transcription factors, including muscle segment homeobox (Msx), and lim containing 
homeobox (Lhx), regulate craniofacial development (Kennedy and Dickinson 2012), and 
knockdown of these genes in mice results in facial abnormalities, including cleft lip/cleft 
palate (Satokata and Maas 1994; Acampora, Merlo et al. 1999; Lanctot, Moreau et al. 1999). 
We have found that knockdown of either retinoic acid or MSX2 and LHX8 induces median 
orofacial clefts, and that this phenotype worsened when all three genes were knocked down. 
Further, both msx2 and lhx8 genes contain RAR consensus binding sites, and we have found 
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that inhibition of retinoic acid signaling decreases the expression of both genes. Our results 
suggest a direct regulation of MSX2 and LHX8 by retinoic acid (Kennedy and Dickinson, 
2012).  
Here, expression of the retinoic acid receptor gamma (RARγ) was found to be highly 
expressed in the orofacial region of Xenopus. Additionally, loss of retinoic acid signaling via 
chemical inhibition of RARγ induced orofacial clefting and reduction of the dorso-anterior 
facial cartilage- suggesting an important role of RA in orofacial development. 
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Methods and Materials 
 
Animals 
Using protocols described in Sive’s laboratory manual (2000), an adult female frog 
was injected with human chorionic gonadotropin (HCG) to induce egg laying. Eggs were then 
collected, fertilized and cultured using standard protocols (Sive 2000). Tadpoles were staged 
according to Niewekoop and Faber (1967).  
 
Whole mount in-situ hybridizations 
   Whole mount in-situ hybridization was performed as previously described by Sive et 
al (2000), omitting the proteinase K treatment. Digoxigenin labeled mRNA probes for retinoic 
acid receptor, RARγ (BC071082.1, openbiosystems: MXL1736-9507435) were used. 
 
Chemical inhibitor treatments 
A 10 mM stock solution of RARγ inhibitor, BMS-453 was prepared by dissolving in 
dimethyl sulfoxide (DMSO). Citral, a RALDH2 inhibitor, was also prepared by a 1:10 
dilution in ethanol. Chemical treatments were carried out in 24 well plastic culture dishes 
containing 1 or 2ml of 0.1X Modified Barth’s Saline (MBS) with five embryos per well. At 
stage 20, embryos were bathed in a combination of inhibitor solution, 1% DMSO in 0.1% 
MBS. Control embryos were bathed in 1% DMSO in 0.1% MBS alone. At stage 35 (40 hpf), 
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embryos were removed from the chemicals incubated in 0.1% MBS solution for another 2-3 
days until stage 43 (70 hpf). They were then fixed with 4% paraformaldehyde (PFA) at 4 C 
overnight.   
 
Collagen II labeling  
Embryos were fixed in 4% PFA for 24 hrs at 4C, washed 3 times in PBT and 
incubated in a 1:10 solution of monoclonal anti-collagen II (DSHB, II-II6B3) for 24hrs at 4 C.  
After 3 washes with phosphate buffered saline solution with Tween (PBT), they were 
incubated in a 1:500 solution of green fluorescent secondary antibody Alexa 488 goat anti-
rabbit (Cell signaling, 4412) for an additional 72 hours at 4 C. After another 3 PBT washes, 
they were incubated in 1:1000 the red counter stain, propidium iodide (PI) (Sigma, P4864) for 
24 hours. Following one final PBT wash to remove PI, embryos were imaged using a Nikon 
C1 confocal microscope. 
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                                                         Results 
 
RALDH2 and RARγ are expressed in complementary and overlapping regions of the 
maxillary and nasal prominences.  
It has been shown that retinoic acid alters structures derived from the first pharyngeal 
arch (Dupe and Pellerin 2009).  To further examine this, the retinoic acid signaling molecules 
expressed in the orofacial region prior to upper lip and palate development needed to be 
determined. Microarray analysis revealed that pathway components, RALDH2 and RARγ, 
were enriched in the embryonic mouth and surrounding tissues ((Dickinson and Sive 2009) 
and unpublished). Xenbase expression database and other published reports support this data 
(Bowes JB 2011; Lynch, McEwan et al. 2011). The literature indicates that other Raldh genes 
(Raldh1, Raldh3) are confined to the eye at the stages of interest. We previously showed that 
Raldh2 was expressed in the orofacial region (Kennedy and Dickinson, 2012), and that RARγ 
is the only retinoic acid receptor (RARα, RARβ, RARγ), expressed in the head at the same 
time as RALDH2 (Dolle 2009; Lynch, McEwan et al. 2011).  Using an mRNA in-situ probe, I 
also examined the expression of RARγ during mouth formation.  
The expression of RARγ was mostly localized in pharyngeal arch 1 and its derivatives, 
just surrounding the presumptive mouth during the time examined (Fig 1 C). Specifically, at 
stage 28 (32 hpf), expression was seen in the medial nasal prominence and paired maxillary 
nasal prominences. The RARγ expression domain directly borders and overlaps with that of 
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Raldh2 (Kennedy and Dickinson, 2012). This data raised the hypothesis that retinoic acid 
signals originating in the mouth and nasal prominences are received by receptors in the 
surrounding maxillary and medial nasal prominences. To test this hypothesis, I performed loss 
of function experiments using chemical inhibition of RARγ and Raldh2.  
 
Decreased retinoic acid signaling results in a median orofacial cleft  
Because of the expression pattern of RARγ revealed from in-situ results, it was 
hypothesized that RARγ is a major receptor for retinoic acid in the developing orofacial 
region. To test this, the well characterized RARγ antagonist, BMS-453 (Chen, Pan et al. 2004; 
Cartry, Nichane et al. 2006; Huang, Ma et al. 2011) was applied to embryos. While this 
inhibitor may also target other RAR genes (α,β) to a small extent, these receptors are not 
expressed in the orofacial region at the time frame examined (Dolle 2009). Thus, it is assumed 
that BMS-453 was primarily targeting RARγ at the time investigated. Embryos at stages 24-
30 (26-35 hpf) were treated with BMS-453 during early orofacial development when RARγ is 
expressed in the facial prominences. At stage 30, (35 hpf) treated embryos were washed out of 
the inhibitor and allowed to develop to stage 43 (66 hpf). To determine the best concentration 
for treatment, several titration experiments were performed. At very low concentrations 
(0.025-0.075 uM ), embryos were unaffected by the inhibitor (n=15 per concentration; 3 
trials).  However, it was found that any concentration between 0.10 uM- 8.5 uM resulted in a 
small mouth with an obvious median facial cleft that extended dorsally (n=66/92) compared 
A 
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to normal shaped mouths in 100% of controls. Additionally, other facial deformities like 
narrowing of the space between the eyes, small misshapen eyes, protruding lens, and hyper-
pigmentation were seen in most (n= n=72/92; 78.3%) treated embryos (Table 1, Fig 2 A,B). 
A range of 0.25 and 1.0 uM was determined to be the best concentration, as 100% of embryos 
exhibited median facial clefts (0.25 uM and 1 uM: 3 experiments, n= 15 each dose; 0.5 uM 
and 0.75 uM: 2 experiments, n=10 each dose) (Fig 2 A,B).  
I also performed loss of function of RALDH2 via application of the RALDH2 
inhibitor, Citral, to embryos during facial prominence specification (stage 24-30, 26-35 hpf). 
Several titration experiments produced inconsistent results, with high rates of lethality at 
concentrations ranging from 3.65E-3 uM to 116 uM (Supp Table 1). Based on these initial 
titrations, it was later determined in our lab that a concentration of 100 uM Citral was not 
lethal and consistently produced a median orofacial cleft in over 80% of embryos (Kennedy 
and Dickinson, 2012).  
 
Decreased retinoic acid signaling results in defects of the dorso-anterior cartilage  
In addition to the median orofacial cleft found in BMS-453 treated embryos, it was 
observed that these embryos also exhibited narrower faces. Therefore, it was hypothesized 
that loss of retinoic acid signaling may result in abnormal formation of the jaw cartilages 
which give the face its width. To test this, cartilages were examined via 
immunohistochemistry with a collagen II marker, the primary cell type found in facial 
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cartilage (Ustunel, Cayli et al. 2003). Cartilages contributing to the palate and jaw were either 
missing or malformed in embryos treated with a 1 uM solution of BMS-453 (Fig 3 A-D). 
Meckel’s cartilage, a temporary structure that gives rise to the lower jaw, was absent in 100% 
of treated embryos (Fig 3 B-D; 2 experiments; n=10) The cerathoyal and basihyal structures 
were both present in treated embryos; however, they were reduced in size and misshapen in 
all embryos (Fig 3 B-D; 2 experiments; n=10). There are normally four brachial cartilages 
that will give rise to the gills (Fig 4A), however, 70% of the treated embryos only had two of 
these four (Fig 3 B-D; 2 experiments; n=10). Control embryos exhibited normal cartilage 
structures (Fig 3 A, 2 experiments; n=10). Whether this phenotype arises because loss of 
retinoic acid does not allow enough cells to be generated, or that retinoic acid is required for 
chondrocyte differentiation remains, unclear.  
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Discussion 
 
Retinoic acid signaling pathway members are expressed in the facial prominences 
Complex interactions of epithelium, endoderm, mesoderm, and cranial neural crest are 
necessary for the proper formation of the head and face. Further contributing to this 
interaction is the effect of the developmental morphogen, retinoic acid, during pharyngeal 
arch and facial prominence formation (Mendelsohn, Lohnes et al. 1994; Brickell and 
Thorogood 1997; Niederreither, Vermot et al. 2003; Mark, Ghyselinck et al. 2004; Kopinke, 
Sasine et al. 2006; Abe, Maeda et al. 2008; Bothe, Tenin et al. 2011). Indeed, our in-situ 
hybridization results of the retinoic acid receptor RARγ revealed abundant expression in the 
first pharyngeal arch and medial nasal prominence at stage 24 (Fig 1 C) which give rise the 
upper lip, primary palate, and jaw elements according to fat mapping experiments (Kennedy 
and Dickinson, 2012). Moreover, the RARγ expression domain directly borders and overlaps 
with that of RALDH2. During stages 24-30 (26-35hpf), expression of Raldh2 was found to be 
localized in the presumptive mouth area and a region corresponding to the medial and lateral 
nasal prominences bordering the frontonasal prominence (Kennedy and Dickinson, 2012). 
Since RA can diffuse to target cells, this suggests that the targets of retinoic acid originating 
in the embryonic mouth are potentially in the surrounding tissue. Taken together, these results 
suggest that retinoic acid signaling contribute to the formation of the upper lip and palate.  
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Retinoic acid regulates formation of the upper lip and facial cartilages independent of neural 
crest and other signaling centers 
Retinoic acid has been well characterized for its role in craniofacial patterning, 
however, less is known about its role in upper lip and primary palate formation. When retinoic 
acid signaling was depleted via inhibition of RARγ, I showed that embryos exhibited severe 
facial abnormalities- including median facial clefts  Our lab has also shown through 
transverse sections of the orofacial region, that this cleft was lined with epithelium and 
extended through the palate (Kennedy and Dickinson, 2012). We also found no change in 
either apoptotic or proliferating cells in BMS-453 treated embryos directly following 
treatment time, suggesting BMS-453 is not likely to be toxic. Later in development, however, 
treated embryos showed a facial narrowing accompanied by a significant decrease in mitotic 
cells (Kennedy and Dickinson 2012). This suggests that loss of retinoic acid may disrupt 
genes that regulate the cell cycle, a mechanism proposed for many teratogens that induce 
facial clefts (Del Bene and Wittbrodt 2005). Cell cycle inhibition alone does not mimic the 
retinoic acid facial phenotype; however, indicating an additional role of retinoic acid in cell 
differentiation and/or movements during face development (Dickinson and Kennedy 2012). 
We also found impaired cell proliferation in the facial prominence mesenchyme of inhibitor 
treated embryos (Dickinson and Kennedy 2012). This decrease in growth may account for the 
failure of the cartilages to form, as supported by my antibody labeling results. Indeed, this 
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provides an explanation for the loss of collagen II protein seen in embryos deficient in retinoic 
acid signaling (Fig 3 A-D).  
Others have shown that the brain and nasal placodes also function as major signaling 
centers in orofacial development (Song, Hui et al. 2004). It follows then, that defects in either 
structure may affect development of upper lip and primary palate secondarily. After 
examination of neural structures after BMS-453 treatment using a tubulin marker, our lab 
found no gross morphological defects in the brain and nasal pit, thereby discounting these 
structures as signaling centers (Kennedy and Dickinson 2012).  
Disruption of retinoic acid signaling affects palate and upper lip associated structures 
derived from neural crest. This therefore calls into speculation that retinoic acid deficiency 
affects the specification or migration of the neural crest. However, our lab showed no obvious 
difference in the in-situ expression pattern of the neural crest marker, AP-2, in retinoic acid 
deficient embryos compared to controls (Kennedy and Dickinson, 2012). This supports mouse 
studies in which ablation of RARγ/β in the cranial neural crest cell lineage did not perturb 
neural crest migration or specification (Dupe and Pellerin 2009). These same mice also 
exhibited a median orofacial cleft similar to those observed in Xenopus. 
 
Retinoic acid may be acting through homeobox genes in the developing face  
Retinoic acid has long been known to regulate hox genes in the developing brain 
(Glover, Renaud et al. 2006), and we have also shown that RA signaling regulates the 
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homeodomain containing genes, msx2 and lhx8, in the facial region (Kennedy and Dickinson 
2012). Further, we found that MSX2/LHX8 morphants exhibited similar defects as RARγ 
inhibitor treated embryos, such as median facial clefts, malformed cartilages, and decreased 
proliferation in facial prominence mesenchyme. Additionally, low level of MSX2/LHX8 
morpholino knockdown coupled with application of a low concentration of RARγ inhibitor 
resulted in a synergistic worsening of these defects (Kennedy and Dickinson 2012). These 
results suggest that retinoic acid regulates facial prominence development through these two 
genes. 
In support of our work, others have shown that changes in retinoic acid signaling alter 
msx2 expression in the facial prominences in both mice and chick (Brown, Robertson et al. 
1997; Song, Hui et al. 2004; Washbourne and Cox 2006), and that homeobox genes target cell 
cycle genes regulating the tissue growth of many organs (Del Bene and Wittbrodt 2005). 
MSX2 ordinarily maintains the facial mesenchyme in a proliferative undifferentiated state 
during development (Ishii, Merrill et al. 2003), and has been reported to control cell cycle 
directly by regulating cyclin D (Hu, Lee et al. 2001). Lhx genes have also been shown to 
regulate cell proliferation in the forebrain (Porter, Drago et al. 1997). Retinoic acid may 
regulate these two genes directly- since msx2 contains verified retinoic acid response 
elements, in addition to several RAR consensuses binding sites our lab has found in both 
genes in Xenopus tropicalis (Alappat, Zhang et al. 2003; Glover, Renaud et al. 2006; Kennedy 
and Dickinson 2012) - or it may be an indirect mechanism via intermediate pathways. 
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Retinoic acid signaling has been implicated in regulating bone morphogenetic protein (BMP) 
and fibroblast growth factor (FGF) pathways during craniofacial development (Song, Hui et 
al. 2004; Abe, Maeda et al. 2008). BMP has been shown to control msx genes in mice and 
chick, and FGF has been seen to regulate LHX8 during development of the chick palate 
(Inoue, Kawakami et al. 2006; Jugessur, Farlie et al. 2009; Greene and Pisano 2010). Such 
integration of signaling pathways could explain why perturbation of BMP, FGF, and RA can 
similarly effect facial development.  
 
Proposed model of retinoic acid signaling in the developing facial prominences 
Based on these results, I have developed a model of the role retinoic acid signaling 
plays in regulating orofacial development. During normal development, retinoic acid 
regulates gene expression, possibly by directly controlling transcription of genes containing 
retinoic acid response elements (RAREs). Alternatively, retinoic acid may indirectly target 
transcription via interaction with chromatin remodelers or other proteins (Amat R 2011). 
Indeed, chromatin marks indicative of transcriptional silencing are decreased in human cell 
lines treated with retinoic acid (Lee, Villa et al. 2007; Campos and Reinberg 2009). In either 
case, these genes regulate proper development of the palate and the cartilage structures of the 
face and jaws by such mechanisms as cell proliferation, apoptosis, and differentiation. This 
subsequently allows proper fusion of the facial prominences in the midline, establishing the 
properly formed orofacial region (Fig 4). When retinoic acid signaling is disrupted, target 
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genes are inappropriately expressed and thus decrease these processes in the palate and jaws. 
This then can cause incomplete fusion of the facial prominences at the midline, creating the 
median facial cleft seen in retinoic acid deficient embryos (Fig 5).  
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Future Directions  
 
I have shown that retinoic acid is important in the developing face, and that deficiency 
induces a median orofacial cleft, malformation of the jaw cartilages, and other facial 
deformities. The mechanism behind this remains unclear. Therefore, more investigation of 
retinoic acid regulation of the developing face is required.  
 
Further assessing retinoic acid regulation of msx, and lhx8  
Our lab has shown that retinoic acid regulates transcription of msx2 and lhx8. It is 
unclear, however, whether this is through direct binding of retinoic acid to RARE domains in 
the promoters of these genes; or indirectly. The presence of RARE sites in both genes 
suggests the former; although a DNA-protein interaction assay, such as a gel shift or 
chromatin immunoprecipitation (ChIP), would need to be performed to support this. Further, 
how msx2 and lhx8 function is also not well understood. It is possible that they share a similar 
cellular activity, or they may regulate similar processes by regulating expression of similar 
genes. Alternatively, one may regulate transcription of the other. By determining the exact 
roles of these proteins, I will be able to further clarify their function in orofacial development.   
 
 
Other genes regulated by retinoic acid signaling  
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It is possible that RA signaling regulates genes upstream of msx2 and lhx8 and in this 
way indirectly controls their transcription. It is also possible that RA signaling controls a 
number of other genes in separate pathways that are important in growth and differentiation of 
the facial prominences. Indeed, our microarray data has yielded several candidate genes that 
to follow up on. RT-PCR, in situ hybridization, and knock down studies of any of these genes 
will further our knowledge of the role retinoic acid plays in the complex relationships 
governing proper formation of the face. Additionally, any overlap in genes affected by both 
retinoic acid and folic acid signaling-as determined by gene expression analyses- can be 
compared to investigate common target genes and further elucidate how proper orofacial 
development occurs.  
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Chapter 2: The role of folic acid in orofacial development 
 
Folate and its relatives, vitamins B6 and B12, are imperative for DNA synthesis, 
repair, and methylation in early development. Plasma folate enters a target cell either by 
binding to transmembrane folate receptors (FOLR) or via carrier mediated transport by folate 
binding proteins (FOLBP) or reduced folate carriers (RFC). Once inside the cell, it undergoes 
a series of reduction reactions. Conversion from dihydrofolate (DHF) to tetrahydrofolate 
(THF) by the enzyme dihydrofolate reductase (DHFR) makes the molecule metabolically 
active and allows it to accept methylene groups from amino acid donors, serine and glycine. 
At this point, methylene-THF can act as a substrate for the one-carbon transfer reactions 
necessary to synthesize and repair DNA and RNA. Alternatively, it can be reduced to methyl-
THF by the enzyme methylene tetrahydrofolate reductase (MTHFR) and act as a methyl 
donor for methylation reactions (Supp Fig 1) (James, Pogribna et al. 1999). DNA methylation 
is critical to the developing embryo, as it regulates which genes are expressed and which are 
silenced (Miranda and Jones 2007). Perhaps its most important role, folate is also responsible 
for several one carbon transfer reactions that ultimately produce purines and pyrimidines 
during DNA replication and synthesis. Indeed, high levels of folate pathway enzymes are 
expressed in cells undergoing rapid proliferation (Lucock 2000). Evidence shows that use of 
folic acid antagonists or dietary deficiency of the molecule during pregnancy is correlated 
with a higher incidence of birth defects, particularly neural tube defects and facial clefts 
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(Hernandez-Diaz, Werler et al. 2000). Further, mutations in the human folate carrier protein 
(RFC1) have also been correlated with cleft lip (Vieira, Cooper et al. 2008). In mice, 
deficiency in the folate binding protein that transports folic acid into epithelial cells results in 
multiple defects, including orofacial deformities (Tang, Santillano et al. 2005). Because of the 
established importance of folate in fetal development, pregnant mothers are advised to take a 
supplement of a synthesized version of the compound called folic acid. Folic acid intake 
during pregnancy helps protect the developing embryo from craniofacial defects as well as 
neural tube defects (Finnell, Greer et al. 1998). The methyl donors for histone and DNA 
methyltransferases necessary to mediate gene and microRNA expression (Choi, Friso et al. 
2005; Ichi, Costa et al. 2010; Shookhoff and Gallicano 2010) are generated by metabolism of 
folic acid, so folate deficiencies can result in defects of neural tube closure (Finnell, Greer et 
al. 1998; Shookhoff and Gallicano 2010). In addition, folic acid is also fundamental for DNA 
synthesis and repair during cell division (Bohnsack and Hirschi 2004; Friso and Choi 2005). 
It follows, then, that regions of rapid growth- such as the developing facial prominences- 
would be especially sensitive to decreased folic acid during development (Rosenquist and 
Finnell 2001).  
It is currently unknown whether folic acid is required for epigenetic events, cell 
division, or both during orofacial development, so I have therefore begun to investigate the 
endogenous role of folate signaling.  Here, dihydrofolate reductase and a folate carrier protein 
were both shown to be highly expressed in the orofacial region of Xenopus. Additionally, loss 
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of folic acid signaling during neural crest migration induced craniofacial abnormalities 
including cartilage malformation, orofacial clefting, decreased cell proliferation and increased 
apoptosis. These results suggest that folic acid is an important regulator in the development of 
the face and mouth.  
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Methods 
 
Animals 
Using protocols described in Early Development of Xenopus Laevis: A Laboratory 
Manual (Sive, Grainger et al. 2000), an adult female frog was injected with human chorionic 
gonadotropin (HCG, Sigma CG10) to induce egg laying. Eggs were then collected, fertilized, 
and cultured using standard protocol (Nieuwkoop and Faber 1967; Sive, Grainger et al. 2000), 
and staged according to Niewekoop and Faber (1967).  
 
Whole mount in-situ hybridizations 
   Whole mount in-situ hybridization was performed as previously described by Sive et 
al (2000), omitting the treatment with proteinase K, washes with 2X SSC buffer following 
bleaching, and incubation in warm hybridization buffer following removal of probes. 
Digoxigenin labeled mRNA probes for dihydrofolate reductase, dhfr (BC084841.1, 
openbiosystems: EXL1051-8947369) and the solute carrier family folate transporter, slc19a1 
(BC073675.1, openbiosystems: MXL1736-9507216) were used.   
 
Methotrexate (MTX) treatments 
A range of MTX concentrations were tested to determine that which would yield 
consistent phenotypes. First, a 0.25 uM methotrexate (MTX) stock solution was prepared by 
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dissolving MTX (Sigma, A6770) in sodium bicarbonate (250 nM). A titration experiment was 
then carried out in which the 0.25 uM stock was combined with 1% dimethyl sulfoxide 
(DMSO), and 0.1X MBS (Modified Barth’s Saline, ph 7.8) to yield concentrations ranging 
from 110 uM to 2200 uM. Control solution consisted of 250 mM sodium bicarbonate, 1% 
DMSO and buffer alone. 
A second stock solution was tested, in which MTX was dissolved in DMSO at a 
concentration of 100 mM. Another titration experiment was then carried out in which the 100 
mM stock was combined with 1% dimethyl sulfoxide (DMSO), and 0.1X MBS (Modified 
Barth’s Saline, pH 7.8) to yield concentrations of 11 uM t, 55uM, and 110 uM. Control 
solution consisted of 1% DMSO and buffer alone. 
Chemical treatments were carried out in 24 well plastic culture dishes with five 
embryos per well in a total volume of 2 mL. At stage 20, MTX solution was added to all 
embryos except controls, which were instead incubated in sodium bicarbonate, DMSO, and 
MBS alone. At stage 30 (35 hours), embryos were removed from the inhibitor by washing 
three times in 0.1X MBS, placed in a 10 cm Petri dish with 10 mL of 0.1X MBS, and 
incubated until stage 42-43 (80-87 hours). They were then fixed with 4% PFA (24 hrs at 4C) 
for further analysis.  
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Immunohistochemistry  
Phosphorylated Histone H3 labeling 
Fixed embryos were incubated in 1:1000 polyclonal anti-phosphorylated histone H3 (PH3) 
(Millipore, 06-570) primary antibody for 96 hours at 4 C. Next, embryos were incubated in 
1:500 fluorescent secondary antibody Alexa 488 goat anti-rabbit (Cell signaling, 4412) 
(Invitrogen, A11004) for 72 hours. They were then incubated in a 1:1000 solution of the 
counter stain propidium iodide (Sigma, P4864) for 24 hours. Embryos were imaged using a 
Nikon C1 confocal microscope.  
 
Cleaved Caspase-3 labeling 
Embryos were fixed for 4 hours at room temperature, and sectioned in 100 uM 
sections using a Leica VT100P vibratome. They were then blocked for three hours in Normal 
Goat Serum and 5% Bovine Serum Albumin at room temperature. Embryos were then 
incubated in a 1:1000 solution of cleaved caspase-3 (Cell signaling, 9661S) primary antibody 
for 48 hours at 4C. Next, they were incubated in 1:500 fluorescent secondary antibody Alexa 
488 goat anti-rabbit (Cell signaling, 4412) (Invitrogen, A11004) for 24 hours. Finally they 
were incubated in a 1:1000 solution of the counter stain propidium iodide (Sigma, P4864) for 
24 hours. Sections were imaged using a Nikon C1 confocal microscope.  
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Alcian Blue Staining 
Cartilages were stained using standard protocols with some modifications (Taylor W 
1985). Embryos were fixed overnight in Bouins fixative at 4C. After washes in 70% Ethanol, 
there were incubated in Alcian blue stain (0.1 mg/ml Alcian Blue in 1 part acetic acid: 4 parts 
EtOH) for 3-4 days at room temperature. Embryos were then washed in 1% HCL in 70% 
EtOH for 1-2 days and cleared in 2% potassium hydroxide and glycerol.  
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Results 
 
Expression of folate pathway molecules in the developing face 
Components of the folate pathway have been very poorly characterized in the 
orofacial region of Xenopus. Therefore, expression of two key components of the pathway 
was examined: the enzyme that converts folate to the metabolically active form, dihydrofolate 
reductase (DHFR) and the carrier molecule, folate transport protein SLC1A19.  In- situ 
hybridization of both molecules at various development stages revealed similar expression 
patterns primarily in the head (Fig 6 A-L) with some expression throughout the neural tube 
and tail. At approximately 24-44 hpf, expression was abundant in the entire head, especially 
in streams of neural crest (st. 24, 26 hpf) (Fig 6 A,B,G,H).  In later stages, expression was 
found in the branchial arches and in regions surrounding the primary mouth (Fig 6 C-F, I-L 
arrow), with only the cement gland and brachial pouches lacking expression (Figure 6 C-F, 
I-L). After primary mouth opening (~66 hpf), DHFR and SLC19a1expression became 
concentrated in the first pharyngeal arch just surrounding the mouth (Fig 6 E,F,K,L asterisk) 
There was also a high amount of expression surrounding the eye and in the brain (Figure 6 
E,F,K,L). This data prompted the hypothesis that folic acid metabolism is important in facial 
development, as well as eye and brain development. To test this hypothesis, loss of function 
via chemical inhibition of DHFR was performed.  
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Titration of DHFR inhibitor to determine a non-lethal concentration that induces an orofacial 
phenotype 
Methotrexate (MTX) is a well characterized folate antagonist, and has been shown to 
induce neural tube defects as well as craniofacial and heart abnormalities (Jordan, Wilson et 
al. 1977; Del Campo, Kosaki et al. 1999; Lee, Bonner et al. 2012). After developing a 0.25 
uM stock solution dissolved in a 250 mM solution of sodium bicarbonate (Sun, Gui et al. 
2007), embryos were then incubated in a range of concentrations (110-2200 uM) during a 
time frame when facial prominences are being specified. It is important to note that these 
concentrations do not necessarily represent the amount of MTX within the cells of the 
embryo. The inhibitor may not efficiently cross the epithelium. Embryos were treated with 
MTX from stage 20 (22 hpf) to stage 30 (35 hpf), then washed out and allowed to develop 
until stage 43 (85 hpf). Control embryos were treated with sodium bicarbonate alone. With 
only three fatalities (n=3/132; 2.3%) in any concentration of sodium bicarbonate alone, it was 
determined that this was an appropriate control (Table 2). As seen in Table 2, 100% of 
embryos treated with the highest concentrations (1100 uM, 2200 uM) exhibited severe, gross 
abnormalities in the head and trunk, such as truncation, curved body axis, loss of gut coiling, 
narrow heads, small close-set eyes, and hyper-pigmentation. Embryos treated with 1100 uM, 
in particular exhibited high rates of embryonic lethality (Table 2). Lower concentrations also 
resulted in 100% of embryos exhibiting abnormalities in the head such as narrow heads, small 
close-set eyes, and hyper-pigmentation. These embryos, however, exhibited fewer trunk 
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malformations with some proper gut coiling and less severe truncation and curvature of the 
body axis. The most common defects seen at all doses were decreases in eye size, decreases in 
facial width, and hyper-pigmentation (Fig 7 A,B asterisks, Fig 8). MTX treated embryos 
looked developmentally younger than their untreated counterparts, and these defects were 
exaggerated as the dosage increased. At intermediate ranges (220 uM, 440 uM), embryos 
exhibited smaller, misshapen mouths with some embryos not developing a mouth at all. 
Mouth deformities were unaccompanied by severe malformation of the rest of the face and 
body, so these concentrations were assumed to be the most effective with minimal off target 
effects (Fig 8). Additionally, these ranges coincided with those already established by others 
to induce neural tube, cardiac, and craniofacial defects (Sun, Gui et al. 2007).   
 
Determining the source of MTX phenotype variability 
Upon re-testing of intermediate MTX concentrations, none of the phenotypes observed 
in the initial trial were produced- with treated embryos looking identical to controls. 
Inconsistency of the results was suspected to be due to a number of factors, so several 
experiments were performed in order to identify the source of variability. 
 
1. Effect of sodium bicarbonate concentration 
 MTX consumption in humans can result in toxic accumulation of the drug in the 
kidneys. Often, these patients are simultaneously given sodium bicarbonate to increase urine 
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alkalinization and flush the chemical out of the body (Proudfoot, Krenzelok et al. 2004). This 
raised the idea that sodium bicarbonate may also somehow interfere with the stability of MTX 
in solution. Thus, a lower concentration of sodium bicarbonate used to dissolve the MTX was 
tested. MTX was dissolved in the original 250 mM sodium bicarbonate solution and 
compared to one half as concentrated (125 mM). Each MTX stock was then applied to 
embryos staged 22-24 (24-30 hpf) at a concentration of 110 uM. Embryos in either MTX 
dilution were equally affected by the two different concentrations of sodium bicarbonate, with 
abnormalities observed in earlier experiments (Fig 9 A-D). This suggested that the variability 
of MTX efficacy was not due to an interaction with sodium bicarbonate.  
 
2. Effect of MTX dissolved in sodium bicarbonate vs. DMSO 
The second method used to investigate the stability of MTX was dissolving MTX 
powder in 1% DMSO rather than sodium bicarbonate. Another dosage dependent experiment 
was performed with DMSO dissolved MTX at concentrations of 11 uM, 55 uM, and 110 uM 
with embryos of stages 15 and 20 (18-22 hpf) (1 experiment: n= 3 per concentration; Supp 
Fig 2 A-H). This also resulted in an increasing worsening of the MTX phenotype seen in 
earlier experiments (Supp Fig 2 B,D,F,H). Upon repetition of both of these experiments, after 
the MTX stock was stored in the freezer, however, no effect of MTX was observed. This led 
to the conclusion that MTX is extremely unstable in liquid form in DMSO. 
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3. Effect of storage time on diluted/reconstituted MTX  
It was hypothesized that the stability of MTX may decrease after a few weeks, so 
higher concentrations of an older stock were tested to determine if the effectiveness decreased 
over time. Indeed, treated embryos exhibited narrower faces, smaller eyes, hyper-
pigmentation, and shortened, curved body axes, however, these abnormalities were less severe 
than the initial trial at the same concentration. Repetition of these concentrations (110-2200 
uM) using the older stock of MTX resulted in a variety of less severe phenotypes, especially 
at lower concentrations when compared to experiments where newly diluted MTX was used 
(Fig 10). High doses (1100 uM, 2200 uM) of older MTX stocks consistently produced 
abnormalities in the trunk, head, and eyes. These embryos also exhibited narrow faces, hyper-
pigmentation, and small triangular mouths (Fig 10 B). This phenotype was similar in embryos 
treated with lower concentrations of newly dissolved MTX, suggesting a decrease in potency 
over time (Fig 10 A-C). Control embryos treated with any concentration of sodium 
bicarbonate developed normally.  
The above experiments lead to the conclusion that MTX is unstable after being 
dissolved, and must therefore be dissolved immediately prior to treatment. Therefore, the rest 
of the results are only those in which newly dissolved MTX in sodium bicarbonate was used. 
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Decreased folic acid signaling during neural crest migration results in facial abnormalities, 
including median orofacial clefts  
Another possible reason for variability in the MTX treatments was that MTX may 
affect development differently if the stage of embryos treated were even slightly different. It 
was difficult to precisely standardize the stages of embryos treated in each experiment 
because the protective outer membrane surrounding the embryo (vitelline membrane) had to 
be mechanically removed in order to allow penetration of the inhibitor through the embryo’s 
outer epithelium. The lag between this process and application of MTX may have caused 
some embryos to be treated with the inhibitor at stages between 20-22 (21-24 hpf), while 
others may have been treated at slightly later stages between 23-25(25-28 hpf). While this is 
only a small window in developmental time; it is in fact a crucial time point. During stages 
20-22, cranial neural crest cells are migrating into the facial prominences. By stage 24, they 
have already reached their final location and begun to differentiate. Because of the known role 
of folate in neural crest cell migration and possibly differentiation (Boot, Steegers-Theunissen 
et al. 2003; Li, Shi et al. 2011), the loss of DHFR signaling via MTX may affect this cell 
population differently before and after migration. To address this, MTX was applied at time 
frames preceding, during, and after neural crest migration.  
 A) Pre-neural crest cell migration  
To examine loss of folic acid signaling prior to neural crest migration,  fresh MTX 
was dissolved in fresh 250 mM sodium bicarbonate and applied to embryos at either stages 15 
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and 20 as described above at concentrations of 110 uM, 1100 uM, and 11000 uM. As seen in 
Figure 11 (A-D), this resulted in a dose dependent worsening of the MTX induced phenotype 
at stages preceding and during neural crest migration. Embryos at the lowest concentration 
(110 uM) exhibited some reduction in size and axial curvature (Fig 11 B). At an 1100 uM 
concentration, embryos had lost all proper gut coiling, had extremely narrow faces with close 
set eyes, and were about half the length of control embryos. Additionally, these embryos 
showed hyper-pigmentation and axial curvature (Fig 11 C).  Embryos at the highest 
concentration (1100 uM) exhibited complete failure of gut coiling, hyper-pigmentation and 
extremely narrow faces with close set eyes. These embryos were about a third of the size of 
controls (Fig 11 D). All controls appeared normal (Fig 11 A). 
 B) Post- neural crest cell migration  
Folic acid signaling is also important for the differentiation of neural crest cells in the 
palate, independently of migration (Boot, Steegers-Theunissen et al. 2003). To investigate 
this, embryos were treated with concentrations of MTX ranging from 110 uM to 11000 uM at 
a stage directly after neural crest cell migration (St. 25, 27 hpf). At the lowest concentration 
(110 uM), embryos exhibited minor reduction in size and slight axial truncation (Supp Fig 2 
A). Embryos treated with 1100 uM MTX showed loss of gut coiling, narrower faces, hyper-
pigmentation, and truncation accompanied by axial curvature (Supp Fig 2 B). The highest 
concentration (11000 uM) induced complete loss of gut coiling, narrow faces with close set 
 38 
 
eyes and hyper-pigmentation (Supp Fig 3 C). These defects were not as severe as those seen 
in embryos treated at earlier stages.  
Embryos were also treated with MTX at an even later stage- after neural crest has 
migrated and differentiated. These embryos exhibited no obvious deformities at the lowest 
concentration of MTX (110 uM), with all embryos resembling controls (Supp Fig 3 D). At 
1100 uM MTX, embryos showed slight truncation, axial curvature, and some loss of gut 
coiling; however appeared otherwise normal (Supp Fig 3 E). Embryos treated with the 
highest concentration (11000 uM) were even more truncated with curved body axes, and 
showed an even larger loss of gut coiling (Supp Fig 3 F). Additionally, they had narrow faces 
with close set eyes (Supp Fig 3).   
 These results showed that application of MTX to embryos prior to neural crest cell 
migration produced the most severe phenotypes, suggesting the importance of folate in this 
process. Thus, all subsequent experiments were performed on embryos prior to neural crest 
migration (20-22 hpf).  
 
Loss of folic acid signaling decreases cell proliferation in the facial tissues  
While DHFR inhibition via MTX produced inconsistent and variable results, some 
experiments were successful and yielded an obvious effect of folic acid deficiency. Embryos 
from trials in which fresh MTX was used immediately after creation of stock solution, were 
subsequently used for immunohistochemical analysis.  
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Phosphorylated histone 3 (pH3) is an epigenetic mark indicative of cells undergoing 
metaphase of either mitosis or meiosis (Hans and Dimitrov 2001). Thus, it is a powerful tool 
to observe cells undergoing cell division. Antibody labeling of pH3 in control embryos 
revealed an abundance of dividing cells in the orofacial region during palate and upper lip 
development (2 experiments; n=10; Fig 12 A). MTX treated embryos, however, exhibited a 
drastic decrease in cell division (Fig 12 B). Difference in cells undergoing cell death between 
inhibitor treated and control embryos was also observed using the apoptotic marker, cleaved 
caspase-3 (2 experiments; n=10). Control embryos exhibited some cell death in the 
developing lens, but very little in the orofacial mesenchyme (Fig 12 C). There was a 
noticeable increase in apoptotic cells in MTX treated embryos- particularly in mesenchyme 
directly surrounding the mouth (Fig 12 D). Taken together, these results suggest that both 
increased cell death and decreased cell proliferation contribute to the facial phenotype 
observed in folic acid deficient embryos. 
 
Decreased folic acid signaling results in malformations of the dorso-anterior cartilages 
In addition to changes in cell behavior of the mesenchyme, the decreased number of 
cells seen in MTX treated embryos may have an effect on the developmental of facial 
structures. This, coupled with the facial narrowing of inhibitor treated embryos, led to the 
hypothesis that folate deficiency was disrupting cartilage formation in the jaws and face. To 
test this, Alcian blue staining was performed on stage 43 embryos (85 hpf) after exposure to 
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110 uM, 220 uM, and 440 uM concentrations of MTX as previously described (2 
experiments; n=10 for each concentration). At the lowest concentration (110 uM), facial 
cartilages were severely malformed compared to controls (Fig 13 A,B,E,F). In addition to a 
reduction in size, these cartilages were misshapen and incorrectly placed, although seemingly 
still present (Fig 13 B,F). At a slightly higher concentration (220 uM), MTX treated embryos 
appeared to be missing most cartilages except for reduced cerathoyal and brachial structures 
(Fig 13 C,G). At the highest tested concentration (440 uM), all recognizable structures were 
absent, with only small remnants of cartilage located centrally (Fig 14 D,H). The loss of facial 
cartilage as MTX concentration increases suggests a pivotal role of folic acid in cartilage 
formation. 
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Discussion 
 
Folic acid metabolism is an important regulator in the developing face 
Folic acid is known to be critical in the closure of the developing neural tube (Ross 
2010); however, not much is known about the role of folate pathway genes in the face. In fact, 
only the reduced folate carrier protein (RFC) has been shown to be localized in the face in 
Xenopus (Tang, Santillano et al. 2005), but it is necessary for neural crest initiation and 
migration (Li, Shi et al. 2011). I found that key components of folic acid metabolism 
including DHFR, the enzyme responsible for the metabolic activation of folate, and the carrier 
protein SLC19a1 are abundantly expressed in the neural crest that contributes to the face, and 
later in the maxillary and mandibular prominences of the first pharyngeal arch, indicating the 
importance of these genes in the development of the upper and lower jaws. I found that 
inhibition of DHFR via the folate antagonist MTX, resulted in several abnormalities such as 
reduced development of facial cartilages, decreased proliferation and increased apoptosis in 
the facial prominence mesenchyme, and mouth malformations accompanied by occasional 
clefting. Developmental deformities by disruption of DHFR action has been supported by 
both correlative and experimental studies. In humans, polymorphisms in the DHFR gene, as 
well as other components of the folate pathway, have been correlated with orofacial clefting 
(Finnell, Greer et al. 1998). Mouse and chick models both reveal malformation or loss of the 
jaw structures under folate deficient conditions (Prescott and Malcolm 2002). Taken together, 
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these results suggest a pivotal role of folic acid in the formation of structures arising from the 
first pharyngeal arch.  
 
Folic acid signaling function to regulate cell proliferation and apoptosis in the facial 
prominences 
Correct synthesis of DNA is critical for proper cell division (Vakifahmetoglu, Olsson 
et al. 2008). Errors in this process cause the cell to either arrest before induction of mitosis for 
repair, or induce apoptosis via initiation of the caspase cell death cascade (Varmark, Sparks et 
al. 2009). Because folate is important in both DNA synthesis and repair, it follows that folate 
deficiency would lead to a decrease in proliferating cells causing a subsequent increase in 
apoptotic cells. Our results support this, with DHFR inhibitor treated embryos exhibiting a 
decrease in proliferating cells and an increase in apoptotic cells in facial prominence 
mesenchyme (Fig 12 A,B). This combination of defects is characteristic of many folate 
deficient models (Kruman, Mouton et al. 2005; Duthie, Mavrommatis et al. 2008; Maldonado, 
Murillo et al. 2011). Indeed, MTX induced folate deficiency in fetal neural crest cells impairs 
proliferation; and mice fed a low folate diet produced offspring with decreased proliferation 
and increased apoptosis in brain cells (Craciunescu, Brown et al. 2004; Zhang, Huang et al. 
2009). Further, folate pathway genes have been found to be overexpressed in a variety of 
tumors, accompanied by a subsequent increase in cell proliferation (Yao, Evans et al. 2009). 
Thus, folate signaling is clearly important in regulating cell division and cell death. In 
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addition to folate being essential for the creation of essential building blocks for cell division, 
it may also regulate cell cycle via other mechanisms (Novakovic, Stempak et al. 2006).  For 
example, it has been proposed to be mediated through ERK1/2 signaling (Zhang, Huang et al. 
2009). The increase in apoptotic cells seen in DHFR inhibitor treated embryos supports a role 
of folate in the cell cycle due to the fact that caspase-3 has been associated with the CDK-p21 
complex responsible for inhibition of progression through the cell cycle, in addition to its 
canonical role in DNA fragmentation (Woo, Hakem et al. 2003). Based on previous studies 
and the expression patterns of DHFR and SLC19a1 I found in-situ, it appears that folate is 
likely regulating the proliferation of neural crest cells and/or later derivatives of the first 
pharyngeal arch. It follows then, that disrupted folic acid signaling leads to malformation of 
structures arising from these cell types.  
 
Folic acid signaling regulates cartilage development in the upper and lower jaws 
Early in development, neural crest cells that migrate into the face contribute to much 
of the cartilage of the upper and lower jaws (Minoux and Rijli 2010). I have shown that folic 
acid deficiency prior to neural crest migration results in severe malformation of upper and 
lower jaw cartilages, especially Meckel’s and basihyal cartilages which support the upper jaw 
and lip (Fig 13). These structures correspond to the high level of DHFR expression seen in the 
first pharyngeal arch via in-situ hybridization (Fig 6 A-F). The second arch derived 
cerathoyal cartilage and the gill supporting branchial cartilages were reduced in inhibitor 
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treated embryos, but still present and not as severely affected. I therefore predict that folic 
acid is required for proper neural crest migration for development of pharyngeal arch derived 
cartilages. However, because treated with the DHFR inhibitor after neural crest migration 
exhibited a less severe facial narrowing, we cannot rule out a role of folate signaling also in 
neural crest differentiation. These results suggest the importance for folate during neural crest 
migration and later differentiation. 
 
Folic acid may also regulate the developing face through an epigenetic mechanism 
Because folate is important in several fundamental cellular processes, it may be 
regulating several aspects of orofacial development. Folate is necessary for the one carbon 
exchange initiating the methionine cycle. Thus, folate deficiency halts this cycle thereby 
affecting proper DNA methylation. Because of folate’s critical role in generating methyl 
groups, it is plausible that in normal development DNA methyltransferases use these methyl 
groups to silence inhibitors of signaling pathways important in growth and differentiation of 
facial prominences. When folate is absent, these normally silent genes are not being 
methylated and therefore are inappropriately expressed.  
Conversely, the methyl groups generated by folate metabolism could instead be used 
to silence miRNAs. Expression of miRNAs due to folate deficiency would lead to repression 
of crucial genes in facial development. Indeed, regions surrounding miRNA promoters are 
enriched with the CpG islands that DNA methyltransferases target. In human lymphoblastoid 
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cells grown on folic acid deficient media, several miRNAs were overexpressed. Interestingly, 
these same miRNA were also over expressed in DNMT1/DNMT3 double knockout cell lines. 
Further, human patients with folic acid deficiency also showed a marked increase in miRNA 
expression compared to those patients with normal folate levels (Shookhoff and Gallicano 
2010). 
In addition, folate metabolism ultimately results in the generation of methyl donor 
groups for DNA methyltransferases (DNMT), so it may be that these methyl groups are being 
used by DNMTs to methylate signaling molecules that inhibit cell proliferation. The 
transforming growth factor, TGFB, for instance is crucial for regulating the mesenchymal 
proliferation, cell movements, and apoptosis necessary for proper formation, elevation and 
fusion of the palatal shelves (Burdett, Waterfield et al. 1988; Kaartinen, Voncken et al. 1995; 
Martinez-Alvarez, Bonelli et al. 2000; Mitchell, Murray et al. 2001; He, Xiong et al. 2008; 
Nawshed 2008). It has been shown in mouse embryonic fibroblasts that folate deficiency 
results in an increase in TGFB signaling (Warner, Webb et al. 2011). This, coupled with my 
data that DHFR inhibition induces decreased proliferation and increased cell death, suggests 
that the orofacial defects seen in Xenopus may arise due to lack of growth in the facial 
prominences. In summary, in addition to its role in DNA synthesis, folate may also be 
regulating orofacial development through precise control of epigenetic events occurring in the 
facial prominences.  
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Identifying the cause of MTX instability  
The stability of a chemical or compound can decrease by undergoing reactions with its 
environment, in which structural changes or intermediate compounds are produced. This then 
may alter the normal function of the chemical or compound (Reusch 1999). I have found that 
the inhibitor, MTX, was most stable directly after dilution in 250 mM concentration of 
sodium bicarbonate solution.  The work done here shows that while DHFR inhibition causes 
an orofacial phenotype in the embryos, a more precise methodology of inducing the 
phenotype needs to be determined. The time course experiments with MTX show that folate 
plays a major role in neural crest development. Antisense morpholinos that need to be injected 
at the one-two cell stage are not ideal as they would likely cause far too much damage to the 
early developing embryo and could result in lethality-illustrating the need for a controlled 
method of folate inhibition. I therefore predict that using another, more stable inhibitor may 
produce consistent results. Methylene tetrahydrofolate reductase (MTHFR) is an enzyme that 
is active further in folate metabolism than DHFR. It catalyzes conversion of the metabolically 
active form of folate to one of the substrates for the homocysteine-methionine cycle necessary 
to generate methyl donor groups. Inhibitors of MTHFR, or of co-factors vitamins B12 and B6, 
may provide a more accurate means of perturbing the pathway, although these methods have 
been poorly characterized in-vivo.  
 
 
 47 
 
Proposed model of folic acid signaling 
Based on these results, I have developed a model for the role folic acid signaling 
regulates orofacial development. During normal development, folic acid initiates the 
methionine cycle thereby generating methyl groups. DNA methyltransferase can then use 
these methyl groups to silence gene expression via DNA or histone methylation in promoter 
regions. These methyl groups may also silence antagonists of transcription factors. In this 
way, folate can control differentiation of the many cell types-cartilage, skin, muscle- that 
make up the face (Fig 14).  
Folate is also responsible for production of purines and pyrimidines, and for correcting 
mistakes made during DNA synthesis (Lucock 2000). By both synthesizing and repairing 
DNA, folate can precisely control which cells enter the cell cycle and which cells undergo 
apoptosis due to DNA errors. This delicate balance of allowing healthy cells to divide while 
initiating programmed cell death in aberrant cells, contributes to proper tissue growth in the 
facial prominences. Thus, folic acid mediated regulation of both differentiation and tissue 
growth is a major player in the proper formation of the orofacial region (Fig 14).     
Disruption of folic acid signaling results in decreased tissue growth and differentiation 
in the facial prominences. Deficiency in folate leads to a reduction of methyl reactions, 
subsequently leading to decreased DNA and histone methylation and mis-regulation of 
appropriate gene expression. Differentiation of the various cell types is thus reduced or 
absent, leading to abnormal development of cartilage, muscle, and epithelium. In addition, the 
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decrease in folate mediated DNA synthesis and repair leads to an accumulation of abherrent 
cells. These cells fail to divide and undergo apoptosis, leading to a subsequent decrease in the 
outgrowth of facial prominence tissues. Thus, reduction in both differentiation and growth in 
the facial prominences under folate deficient conditions, leads to abnormalities in orofacial 
development (Fig 15). Further experiments are necessary to tease apart these relationships; 
however, the work we’ve done allows us to begin making inroads into the complex 
mechanisms regulating proper formation of the orofacial region.  
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Future directions 
 
I have shown that components of the folic acid pathway are expressed in the  
developing face, and that deficiency induces orofacial deformities, malformation of the jaw 
cartilages, and increased cell death with a decrease in proliferation in the facial prominences. 
It is unclear how folic acid regulates proper formation of the face, and so further investigation 
into these processes needs to be performed.  
 
The relationship between folic acid signaling and neural crest cell development 
I have shown that folic acid deficiency prior to neural crest migration results in a more 
severe malformation of the orofacial region that deficiency induced at later time points (Supp 
Fig 2). This suggests that folate may regulate genes or survival of neural crest important in 
neural crest development. In order to support this hypothesis, I will perform in-situ 
hybridization of neural crest markers before and after MTX treatment.  To further determine 
whether folate is directly affecting neural crest cells, or providing environmental signals along 
their migration path, I will perform a transplant experiment. Cranial neural crest tissue from a 
folic acid deficient embryo that has been labeled will be surgically removed prior to migration 
and transplanted onto a normal embryo of the same stage. The converse experiment will also 
be performed. In this way, I could determine if folate is affecting development and induction 
of the neural crest, or is producing signals during their migration. These experiments have the 
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potential to better understand the protective nature of folate against orofacial malformations 
during early development.  
 
Examination of other folate pathway components 
The inhibitor used in all experiments described above, MTX, perturbs the folate 
pathway by inhibiting dihydrofolate reductase (DHFR). To examine the specificity of MTX, I 
will attempt to reverse the orofacial phenotype by simultaneously treating embryos with MTX 
and folic acid. If a rescue is seen, this suggests that MTX does in fact specifically perturb the 
folate pathway. In addition, I will also try to rescue the MTX phenotype with other 
downstream components of the folate pathway such as cofactors and other B vitamins.  
DHFR is a highly important enzyme in the folate pathway- as it catalyzes the 
conversion of folate to its metabolically active form. This occurs fairly early in the pathway-
before transport into target cells and initiation of the cycles necessary for DNA 
synthesis/repair or DNA methylation. By inhibiting more downstream pathway components, I 
will be able to pinpoint if one or both of these cycles is involved in the formation of the 
orofacial region. For instance, I can inhibit enzymes that disrupt folate’s feed into the 
methionine cycle; or I can inhibit different proteins to disrupt folate’s role in the DNA 
synthesis cycle. Determining effective ways of inhibiting folate signaling at various points in 
the pathway will allow a better understanding of how disruption affects orofacial 
development.  
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Target genes of folic acid signaling 
It is clear that folic acid deficiency creates a variety of deformities in the developing 
face. To determine the genes most affected, I will perform RT-PCR on normal and inhibitor 
treated embryos. I will first examine expression of transcription factors important in growth 
and differentiation such as lhx8, msx2, fgf8, and bmp4- all of which have been shown to 
regulate face development. I will then also examine expression of genes important in neural 
crest development and migration, such as twist, snail, and slug. Finally, the decrease in 
proliferating cells and increase in apoptosis seen in inhibitor treated embryos suggests that the 
cell cycle is being affected by folic acid signaling. To test this, I will examine expression 
levels of checkpoint genes, wee1, as well as cell cycle regulators such as cyclins. As an 
alternative to RT-PCR, I can also perform a microarray analysis. 
While RT- PCR or microarray will determine which genes are up- or down-regulated 
by folic acid signaling, they still will not provide many clues as to the mechanism behind this 
regulation. Due to its critical role in initiation of the methionine cycle, folic acid may be 
acting through an epigenetic mechanism. To determine if folate regulation occurs via DNA 
methylation, I can perform bisulfite conversion on DNA extracted from normal and inhibitor 
treated embryos. This will convert all unmethylated cytosine residues to uracils and leave all 
methylated cytosines unchanged. This will allow sequencing of either specific genes or the 
whole genome to determine a difference in methylation patterns. Folate signaling may also 
play a role in histone methylation, so I will also examine expression of permissive and 
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silencing histone marks between normal and inhibitor treated embryos using either Western 
blots or immunhistochemistry. Alternatively, I could also perform a chromatin 
immunoprecipitation (ChIP).  This combination of experiments will ultimately lead to a better 
understanding of how and why folic acid signaling is so crucial to proper orofacial 
development.  
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Summary 
 
Clearly, both retinoic acid and folic acid signaling pathways are extremely important 
to the developing embryo- particularly in patterning the orofacial region. Inhibition of key 
enzymes in either pathway both result in similar malformation of the mouth and jaws, as well 
as disruption of proliferation and apoptosis in the developing facial prominences. This 
suggests that perhaps the two pathways converge on a similar mechanism. They may regulate 
the transcription of the same genes, such as growth factors and hox genes, required for growth 
and differentiation of the face; or they may be acting through an epigenetic mechanism, such 
that they modify gene expression by either DNA methylation or histone modifications. 
Folate’s role in the methyl group generating methionine cycle, for instance, indicates an 
inextricable link between folic acid and DNA methylation (James, Pogribna et al. 1999) and 
both correlative studies and animal models show that decreased maternal folic acid results in 
facial clefting (Finnell, Greer et al. 1998; Hernandez-Diaz, Werler et al. 2000; Tang, 
Santillano et al. 2005; Vieira, Cooper et al. 2008). Interestingly, an epigenetic mechanism 
may be responsible for retinoic acid induced orofacial anomalies as well. Murine models 
demonstrate that application of retinoic acid not only causes facial clefts, but also disrupts the 
dynamic DNA methylation status of genes required for development of the palate (Kuriyama, 
Udagawa et al. 2008). Further, retinoic acid receptors have been shown to complex with co-
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repressor proteins, acting to recruit histone de-acetylases and silence transcription (Nagy, Kao 
et al. 1997). Alternatively, the two pathways may affect completely different aspects of face 
development- such that folate is important in methylating promoters, while retinoic acid 
functions as a transcription factor to initiate gene expression. What is clear, however, is that 
both pathways play pivotal roles controlling gene expression important in regulating the 
development of the orofacial region.  
While deficiencies in retinoic acid and folic acid have been well known to cause a 
variety of birth defects, I have shown that disruption of both pathways results in similar 
malformations of the orofacial region. The work that I have done is just a small piece in the 
complex puzzle of facial development, but has the potential to lead to a better understanding 
of the relationships that regulate formation of the orofacial region.  
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Figure 1. In situ hybridization of the retinoic acid receptor gamma. 
Stage 28 (32 hpf) embryos showing localization of A.) antisense 
XCG (Xenopus cement gland) as a positive control B.) RAR gamma 
sense as a negative control or  C.)  RAR gamma antisense probes.                                                   
cg- cement gland 
Figures
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Figure 2. Inhibition of retinoic acid 
receptor gamma induces facial clefting. 
A,B.) Light microscope image of BMS -
453 treated embryos C.) Control embryo 
treated with DMSO. Insets are enlarged 
images of embryo mouths.   
cg- cement gland                                             
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Table 1. Initial BMS-453 Titration experiments. 
*Some experiments were performed before the timing of treatment was well established. Thus, higher 
concentrations may appear to have a less severe effect due to application at a time after retinoic acid signaling 
is critical to orofacial development. 
Concentration 
(uM) 
Trials Total 
embryos 
phenotypes observed Facial narrowing, 
small eyes, misshapen 
or absent mouth 
clefts 
0.025 3 15 resembled controls 0% 0% 
0.05 3 15 resembled controls 0% 0% 
0.075 3 15 resembled controls, some with 
smaller eyes 
33.3% 0% 
0.1 4 20 narrow face, small eyes, protruding 
lens 
50% 50% 
0.25 3 15 curved body, narrow face, small 
eyes, protruding lens 
100% 100% 
0.5 2 10 curved body, narrow face, small 
eyes, protruding lens, edema 
100% 100% 
0.75 2 10 curved body, narrow face, small 
eyes, protruding lens, edema 
100% 100% 
1* 3 15 curved body, narrow face, small 
eyes, protruding lens, edema 
33.3% 33.3% 
1.5 1 5 shortened body, narrow face, small 
eyes, protruding lens 
100% 100% 
2.5 1 5 shortened body, narrow face, small 
eyes, protruding lens 
100% 100% 
4.25 1 6 shortened body, narrow face, small 
eyes, protruding lens 
100% 100% 
8.5 1 6 shortened body, extremely narrow 
face, small eyes, protruding lens, 
small malformed mouth 
100% 0% 
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Figure 3. Retinoic acid receptor gamma inhibitor treatment induces cartilage malformations. A.) Confocal 
microscope image of control embryo treated with DMSO and stained with anti-collagen. B-D )Embryos 
treated with a 1 uM BMS-453 concentration tagged with fluorescent anti-collagen. Collagen is labeled in 
green, and all nuclei are counterstained in propidium iodide (red).                                                                                                 
mc- Meckel’s cartilage, ch- cerathoyal, bh- basihoyal, ba- brachial arches  
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Figure 4. Model of normal retinoic acid regulation of orofacial development. 
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Figure 5. Disrupted retinoic acid regulation during orofacial development. 
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Figure 6. Expression of folate pathway molecules in the head. A-F.) 
Expression of synthesis enzyme Dihydrofolate reductase (DHFR) during 
three different developmental stages. G-L.) Expression of folate carrier 
protein SLC1A19 during three developmental stages. Arrow indicates 
presumptive mouth. Asterisk indicates pharyngeal arch 1. 
cg= cement gland; ba= brachial arches 
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Table 2. Establishing a concentration of MTX to illicit an orofacial phenotype. Embryos were 
observed and scored for abnormalities of various tissues. Trunk abnormalities include shortened 
body axis, axis curvature, or tail malformations. Embryos with reduced head size showed narrowing 
of the space between the eyes, shortening of face length, or expansion of cement gland. Eye 
abnormalities include small, underdeveloped eyes or protruding lenses. Mouth abnormalities 
include misshapen mouth opening, smaller mouth opening, or median facial clefts.  
 
 
Concentration 110 uM 220 uM 440 uM 1100 uM 2200 uM Controls 
No effect 0/6 0/6 0/6 0/6 0/6 33/36 
Trunk abnormalities 1/6 3/6 3/6 12/12 6/6 0/36 
Reduced head size 0/6 6/6 6/6 12/12 6/6 0/6 
Eye abnormalities 6/6 6/6 6/6 12/12 6/6 0/6 
Mouth abnormalities 6/6 6/6 6/6 12/12 6/6 0/6 
Edema 0/6 0/6 0/6 0/12 0/6 0/6 
Death 0/6 1/6 2/6 4/12 0/6 
3/36: 1 in 220 uM and 2 in 
1100 uM 
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Figure 7. Common 
MTX induced facial 
abnormalities. A.) 
Control embryo 
treated with sodium 
bicarbonate. B.) MTX 
treated embryo in a 
220 uM solution of 
MTX dissolved in 250 
mM sodium 
bicarbonate. Mouth 
outlined in red dots 
and indicated by 
arrow. Asterisk 
indicates region of 
hyper-pigmentation 
cg= cement gland 
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Figure 8. Phenotypes observed in MTX treated embryos. A total of 56 experiments were 
performed with 295 total treated embryos. Embryos were observed and scored for 
abnormalities of various tissues. Percentages were calculated by dividing the number of 
embryos with a given abnormality by the total number treated at each tested concentration. 
Trunk abnormalities include shortened body axis, axis curvature, or tail malformations. 
Embryos with a reduced head size showed a narrowing of the space between the eyes, 
shortening of face length, or expansion of cement gland. Eye abnormalities include small, 
underdeveloped eyes or protruding lenses. Mouth abnormalities include misshapen mouth 
opening, smaller mouth opening, or median facial clefts. Embryos scored as not affected 
resembled controls. Dead embryos and those with full body edema were scored, with additional 
phenotypes scored separately.  
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Figure 9. Testing the efficacy of MTX in different stock solutions of 
sodium bicarbonate. After dilution of MTX in either A,C.) 250 mM or 
B,D.) 125 mM sodium bicarbonate solution, embryos were incubated 
in a final concentration of 110 uM.  Asterisks indicate anterior of 
embryo. 
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Figure 10. Determining the efficacy of MTX over time. A.) Control embryo treated with a 
440 uM concentration of sodium bicarbonate B.) Embryo treated with a 2200 uM 
concentration of MTX that had been diluted and kept in storage for several weeks. C.) 
Embryo treated with a 440 uM concentration of freshly prepared MTX. Red dots outline 
mouth.  
cg= cement gland  
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Figure 11. Dose dependent phenotypes MTX treated embryos. A.) Representative control embryos 
treated with an 1100 uM sodium bicarbonate solution. B-D.) Representative treated embryos in 
increasing concentrations of MTX dissolved in 250 mM sodium bicarbonate. Anterior is right, posterior 
is left.   
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Figure 12. Cell proliferation and apoptosis in treated and control embryos. A,B.) 
Dividing cells were labeled with mitotic marker pH3 (green) and counterstained 
with propidium iodide (red) to label all nuclei. C,D.) Cells undergoing apoptosis 
were labeled with cleaved caspase 3 (green) and counterstained with propidium 
iodide (red). Arrow head represents median orofacial cleft.  
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Figure 13. Cartilage malformation with increasing MX concentrations. A-D.) Dorsal views. E-
H) Axial view through mouth opening. B-D,F-H.) MTX treated embryos were treated with 
varying concentrations of MTX dissolved in 250 mM sodium bicarbonate. A,E.)Controls were 
treated with sodium bicarbonate alone. Arrows indicate unidentifiable cartilage structures. Blue 
indicates cartilage (Alcian Blue stain).  
ch= cerathoyal, bh= basihyal, ba=brachial arches, mk=Meckel’s 
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Figure 14. Model of normal folic acid signaling during orofacial development.  
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Figure 15. Model of disrupted folic acid signaling during orofacial development.  
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Appendix A- Supplemental Tables 
 
Supplemental Table 1. Citral titration experiments. 
Concentration 
(uM) 
total # # survived phenotypes observed 
11.67 
6 0 Death, embryos falling apart 
116.66 
6 0 Death, embryos falling apart 
1.17 
6 0 Death, embryos falling apart 
2.33 
6 5 
1 dead and falling apart, remaining embryos motionless, eyeless, 
with edema 
1.17E-01 
6 0 Death, embryos falling apart 
3.65E-04 
15 15 resembled controls, 1 embryo with small eyes and edema 
7.29E-04 
15 15 resembled controls 
1.46E-03 
15 15 resembled controls, 1 embryo with small eyes and edema 
3.65E-03 
15 15 resembled controls 
3.65E-03 
15 1 
Death, embryos falling apart, remaining embryo motionless, 
eyeless, with curved spine and edema 
7.29E-03 
15 0 Death, embryos falling apart 
1.46E-02 
45 30 
dead embryos disintegrated, surviving embryos resembled 
controls 
3.65E-02 
15 0 Death, embryos falling apart 
7.29E-02 
15 0 Death, embryos falling apart 
1.46E-01 
20 10 short tails, small eyes, edema, dead ones disintegrated 
8.75E-02 
5 1 Bodies about half the length of controls, edema 
5.83E-02 
5 4 extremely short, edema 
2.92E-02 
15 15 resembled controls; slightly curved bodies 
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Supplemental Figure 1. Schematic of folate metabolism in a target cell. Redrawn 
from (Lee, Bonner et al. 2012). 
Appendix B- Supplemental Figures
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Supplemental 
Figure 2. Effect of 
MTX dissolved in 
DMSO. A,C,E,G.) 
Embryos treated 
with either 
A.)DMSO (as 
controls) or 
C,E,G,) varying 
concentrations of 
MTX at stage 15.  
B,D,F,H.) Embryos 
treated with either 
B.)DMSO or 
D,F,H,) varying 
concentrations of 
MTX at stage 20. 
Arrow heads 
indicate mouth 
opening 
cg= cement gland  
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Supplemental Figure 3. Testing the efficacy of MTX on later developmental stages.  After dilution of 
MTX in 250 mM sodium bicarbonate solution, stage 25 (A-C) and stage 30 (D-F) embryos were 
incubated in either 110 uM (A,D) , 1100 uM (B,E), or 11000 uM (C,F) concentrations.  
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